Cargando…

Lysophosphatidic Acid-Induced Transcriptional Profile Represents Serous Epithelial Ovarian Carcinoma and Worsened Prognosis

BACKGROUND: Lysophosphatidic acid (LPA) governs a number of physiologic and pathophysiological processes. Malignant ascites fluid is rich in LPA, and LPA receptors are aberrantly expressed by ovarian cancer cells, implicating LPA in the initiation and progression of ovarian cancer. However, there is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murph, Mandi M., Liu, Wenbin, Yu, Shuangxing, Lu, Yiling, Hall, Hassan, Hennessy, Bryan T., Lahad, John, Schaner, Marci, Helland, Åslaug, Kristensen, Gunnar, Børresen-Dale, Anne-Lise, Mills, Gordon B.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2679144/ https://www.ncbi.nlm.nih.gov/pubmed/19440550 http://dx.doi.org/10.1371/journal.pone.0005583

Ejemplares similares

High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival
por: Baumbusch, Lars O., et al.
Publicado: (2013)

MicroRNA Regulation of the Autotaxin-Lysophosphatidic Acid Signaling Axis
por: Murph, Mandi M.
Publicado: (2019)

Fibroblast Growth Factor Receptor 3 (FGFR3)–Analyses of the S249C Mutation and Protein Expression in Primary Cervical Carcinomas
por: Dai, Haiyan, et al.
Publicado: (2001)

Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
por: Schaner, Marci E, et al.
Publicado: (2005)

Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers
por: Chi, Jen-Tsan, et al.
Publicado: (2006)

Lysophosphatidic Acid Mediates Activating Transcription Factor 3 Expression Which Is a Target for Post-Transcriptional Silencing by miR-30c-2-3p
por: Nguyen, Ha T., et al.
Publicado: (2015)

PathTracer: High-sensitivity detection of differential pathway activity in tumours
por: Nygård, Ståle, et al.
Publicado: (2019)

Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers
por: Helland, Åslaug, et al.
Publicado: (2011)

Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas
por: Haakensen, Vilde D, et al.
Publicado: (2011)

Mutations for the people
por: Kristensen, Vessela, et al.
Publicado: (2010)

Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity
por: Dannenfelser, Ruth, et al.
Publicado: (2017)

Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2015)

Profiling of microRNAs in tumor interstitial fluid of breast tumors – a novel resource to identify biomarkers for prognostic classification and detection of cancer
por: Halvorsen, Ann Rita, et al.
Publicado: (2016)

The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future Opportunities
por: Breuer, Eun-Kyoung Yim, et al.
Publicado: (2011)

Molecular Epigenetics in the Management of Ovarian Cancer: Are We Investigating a Rational Clinical Promise?
por: Nguyen, Ha T., et al.
Publicado: (2014)

Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load.
por: Helland, A., et al.
Publicado: (1998)

Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy
por: Halvorsen, Ann Rita, et al.
Publicado: (2014)

Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients
por: Halvorsen, Ann Rita, et al.
Publicado: (2017)

Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer
por: Liu, Shuying, et al.
Publicado: (2014)

TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
por: Halvorsen, Ann R., et al.
Publicado: (2016)

Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors
por: Rye, Inga H., et al.
Publicado: (2018)

Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
por: Fleischer, Thomas, et al.
Publicado: (2014)

TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
por: Kringen, Pedro, et al.
Publicado: (2005)

N‐glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome
por: Terkelsen, Thilde, et al.
Publicado: (2018)

Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density
por: Haakensen, Vilde D, et al.
Publicado: (2010)

Cancer Stem Cell Radioresistance and Enrichment: Where Frontline Radiation Therapy May Fail in Lung and Esophageal Cancers
por: Nguyen, Giang Huong, et al.
Publicado: (2011)

Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid
por: Altman, Molly K, et al.
Publicado: (2010)

Biochemical Pathways in Cancer
por: Breuer, Eun-Kyoung Yim, et al.
Publicado: (2012)

Methylation detection oligonucleotide microarray analysis: a high-resolution method for detection of CpG island methylation
por: Kamalakaran, Sitharthan, et al.
Publicado: (2009)

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2014)

Oral language skills and mental health in female prisoners: pragmatic skills are essential
por: Morken, Frøydis, et al.
Publicado: (2023)

2-Carba-lysophosphatidic acid is a novel β-lysophosphatidic acid analogue with high potential for lysophosphatidic acid receptor activation and autotaxin inhibition
por: Fukasawa, Keiko, et al.
Publicado: (2021)

Elevated plasma levels of lysophosphatidic acid and aberrant expression of lysophosphatidic acid receptors in adenomyosis
por: Yang, Bicheng, et al.
Publicado: (2017)

Lysophosphatidic Acid Analogue rather than Lysophosphatidic Acid Promoted the Bone Formation In Vivo
por: Yu, Zi-Li, et al.
Publicado: (2018)

Hypervariable area in the 5' flanking region of GSTP1, previously reported as a minisatellite repeat
por: Nedelcheva Kristensen, V, et al.
Publicado: (2000)

Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features
por: Haakensen, Vilde D, et al.
Publicado: (2011)

Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer
por: Muggerud, Aslaug Aa, et al.
Publicado: (2010)

Lysophosphatidic Acid and Glutamatergic Transmission
por: Roza, Carolina, et al.
Publicado: (2019)

Lysophosphatidic Acid Signaling in Cancer
por: Brindley, David N.
Publicado: (2020)

Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 – 2020 - A population-based registry study from Norway
por: Børø, Siri, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_16k3h461iq08vaqlvtf0kecni4